Recce Pharmaceuticals Ltd (FRA:R9Q)

Market Cap	62.42M -3.5%
Revenue (ttm)	5.73M +26.1%
Net Income	-9.06M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,000
Open	0.1890
Previous Close	0.1940
Day's Range	0.1890 - 0.1890
52-Week Range	0.1490 - 0.4500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States. The company’s lead candidate is RECCE 327 (R327) for the treatment of life-threatening bacterial infections. In addition, its product pipeline comprises R327 Intravenous, which is in Phase I and Phase I/II clinical trial for the treatment of urinary tract infections/urosepsis; and R327 Topical Gel, which is in Phase II clinical trial for the treatment of acute bacterial skin and skin structure inf...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: R9Q

Financial Performance

In fiscal year 2026, Recce Pharmaceuticals's revenue was 9.47 million, an increase of 26.06% compared to the previous year's 7.51 million. Losses were -14.96 million, -30.18% less than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error